Show simple item record

dc.contributor.authorJackson, Carlayne E.
dc.contributor.authorLovitt, Steven
dc.contributor.authorGowda, Neelam
dc.contributor.authorAnderson, Frederick A. Jr.
dc.contributor.authorMiller, Robert G.
dc.date2022-08-11T08:08:07.000
dc.date.accessioned2022-08-23T15:43:27Z
dc.date.available2022-08-23T15:43:27Z
dc.date.issued2006-06-07
dc.date.submitted2011-09-16
dc.identifier.citationAmyotroph Lateral Scler. 2006 Jun;7(2):80-5. <a href="http://dx.doi.org/10.1080/14660820500504587">Link to article on publisher's site</a>
dc.identifier.issn1471-180X (Linking)
dc.identifier.doi10.1080/14660820500504587
dc.identifier.pmid16753971
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27097
dc.description.abstractIn spite of emerging evidence of therapeutic benefit from non-invasive positive pressure ventilation (NPPV), only a minority of ALS patients use this therapy. We examined factors which correlate with use of NPPV in ALS patients. Data were analyzed from the ALS CARE Database on the use of NPPV in patients with FVC less than 50% of predicted and probable or definite ALS based on modified El Escorial criteria. Of the 403 eligible patients, 146 (36%) used NPPV. NPPV compliance was strongly correlated with symptoms of dyspnea and orthopnea as well as with the use of other therapies including PEG tubes, augmentative speech devices, and riluzole. Male gender and household income >$80,000 were also associated with higher NPPV use. There was no correlation between age, race, type of insurance, forced vital capacity, duration of symptoms, ALSFRS-R, caregiver burden or quality of life with the use of NPPV. These data suggest that the factors which are most closely associated with NPPV utilization are symptomatic orthopnea and dyspnea. The findings may be useful in designing prospective studies to examine the factors which might explain the underutilization of NPPV and the optimal use of this treatment.
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=16753971&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1080/14660820500504587
dc.subjectAdult
dc.subjectAmyotrophic Lateral Sclerosis
dc.subjectDatabases, Factual
dc.subjectDyspnea
dc.subjectFemale
dc.subjectHumans
dc.subjectIncome
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMotor Neurons
dc.subjectPositive-Pressure Respiration
dc.subjectSex Factors
dc.subjectSocioeconomic Factors
dc.subjectVital Capacity
dc.subjectHealth Services Research
dc.titleFactors correlated with NPPV use in ALS
dc.typeJournal Article
dc.source.journaltitleAmyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases
dc.source.volume7
dc.source.issue2
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/cor_als/1
dc.identifier.contextkey2241832
html.description.abstract<p>In spite of emerging evidence of therapeutic benefit from non-invasive positive pressure ventilation (NPPV), only a minority of ALS patients use this therapy. We examined factors which correlate with use of NPPV in ALS patients. Data were analyzed from the ALS CARE Database on the use of NPPV in patients with FVC less than 50% of predicted and probable or definite ALS based on modified El Escorial criteria. Of the 403 eligible patients, 146 (36%) used NPPV. NPPV compliance was strongly correlated with symptoms of dyspnea and orthopnea as well as with the use of other therapies including PEG tubes, augmentative speech devices, and riluzole. Male gender and household income >$80,000 were also associated with higher NPPV use. There was no correlation between age, race, type of insurance, forced vital capacity, duration of symptoms, ALSFRS-R, caregiver burden or quality of life with the use of NPPV. These data suggest that the factors which are most closely associated with NPPV utilization are symptomatic orthopnea and dyspnea. The findings may be useful in designing prospective studies to examine the factors which might explain the underutilization of NPPV and the optimal use of this treatment.</p>
dc.identifier.submissionpathcor_als/1
dc.contributor.departmentCenter for Outcomes Research
dc.source.pages80-5


This item appears in the following Collection(s)

Show simple item record